Rexulti Works for Agitation in Alzheimer's, Despite Risks, Says FDA Staff
Por um escritor misterioso
Descrição
Increased mortality risk consistent with other antipsychotics in elderly dementia patients
FDA Approves First Treatment for Alzheimer's Agitation
The Madness of Pop Psychiatry - by Nick Jikomes, PhD
Important News for Older Adults: FDA Approves First Drug to Treat Agitation Symptoms Associated with Dementia due to Alzheimer's Disease - Alliance for Aging Research
Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for Agitation
Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration ( FDA) Advisory Committee Meeting on REXULTI® (brexpiprazole) for the Treatment of Agitation Associated with Alzheimer's Dementia
FDA Approves First Treatment for Alzheimer's Agitation
Frontiers Agitation and Dementia: Prevention and Treatment Strategies in Acute and Chronic Conditions
FDA Approves First Drug to Treat Dementia-Associated Agitation in AD Patients
Alzheimer's drug controversies and scandals: behind closed doors
Frontiers Agitation and Dementia: Prevention and Treatment Strategies in Acute and Chronic Conditions
de
por adulto (o preço varia de acordo com o tamanho do grupo)